ATyr Pharma, a biotherapeutics company focused on a range of rare diseases, has attracted a $76m series E round from investors including healthcare services provider Sphera Global Healthcare.
The round was led by Sofinnova Ventures as well as an unnamed institutional investor in the biotechnology sector. T Rowe Price Associates, Federated Investors, Deerfield, Rock Springs Capital Management, EcoR1 Capital and two other unnamed investors also participated in the round alongside unnamed existing investors.
Founded in 2005, ATyr has raised at least $170m in equity funding from the above investors and Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners, as well as $10m in debt financing from Silicon Valley Bank. The company has not disclosed its series A round.
The latest funding will be used to support a Phase 1b/2 trial for resolaris, the company’s lead drug candidate for facioscapulohumeral muscular dystrophy, a genetic disease that affects skeletal muscles and can lead to severe disability. ATyr will also expand its pipeline.